The influence of genetics on the risk for type 2 diabetes has been suggested by previous research, but new research from the NIH has now outlined in unprecedented detail the role of common genetic variants in the risk for this disease. “Our study has taken us to the most complete understanding yet of the genetic architecture of type 2 diabetes,” said Michael Boehnke, PhD.
While testifying before the Senate Committee on Finance on July 13, 2016, Acting Administrator for CMS Andrew Slavitt said that the agency would consider delaying the implementation of MACRA to address physician and stakeholder concerns. Signed into law in 2015, MACRA will dramatically change the way in which physicians caring for Medicare beneficiaries are paid. The final rule is expected to be released in November of 2016, with an intended start date of January 1, 2017.
Last November, osimertinib (Tagrisso), a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR mutations, including T790M, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastaticEGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) whose disease progressed during or after EGFR TKI therapy.
On May 18, 2016, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq; Genentech) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Sarcomas, a group of malignant tumors that develop in soft tissue and bone, can affect any part of the body but most often occur in the abdomen, arms, and legs. Soft-tissue sarcomas typically form in the muscle, cartilage, fat, blood vessels, nerves, and other connective or supportive tissues, including the tendons and joint linings.
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Opdivo (Nivolumab), a PD-1 Inhibitor, Receives New Indications for Melanoma, NSCLC, and Renal-Cell Carcinoma
Lung cancer, melanoma, and renal-cell carcinoma represent significant burdens for patients and for the healthcare system. In light of the high morbidity and mortality associated with these malignancies and the quality-of-life challenges, there is a marked need for additional therapeutic options that improve outcomes for patients with melanoma, non–small-cell lung cancer (NSCLC), or renal-cell carcinoma.
Odomzo (Sonidegib), a Hedgehog Pathway Inhibitor, FDA Approved for the Treatment of Patients with Locally Advanced Basal-Cell Carcinoma
Basal-cell carcinoma is the most common type of skin cancer, accounting for approximately 80% of nonmelanoma skin cancers. More than 2.8 million new cases of basal-cell carcinoma are diagnosed annually in the United States, and 3000 people die from this disease annually.
Page 1 of 6
Results 1 - 10 of 53
Results 1 - 10 of 53